- Home
- IPHA vs MCRB Comparison
IPHA vs MCRB Comparison
Compare IPHA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | MCRB |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 139.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | IPHA | MCRB |
|---|---|---|
| Price | $1.74 | $8.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | $5.00 | ★ $14.33 |
| AVG Volume (30 Days) | 16.7K | ★ 100.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 2.40 |
| Revenue | N/A | ★ $126,325,000.00 |
| Revenue This Year | $28.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.63 |
| Revenue Growth | N/A | ★ 1672.24 |
| 52 Week Low | $1.57 | $0.36 |
| 52 Week High | $2.63 | $29.98 |
Technical Indicators
Market Signals| Indicator | IPHA | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 30.78 |
| Support Level | $1.73 | $7.12 |
| Resistance Level | $1.90 | $16.14 |
| Average True Range (ATR) | 0.09 | 0.99 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 75.18 | 13.01 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.